Form 4: Cue Biopharma Director, Frank Morich, Awarded Stock Options

Director Frank Morich received a stock option award for 24,400 shares of Cue Biopharma, Inc. stock on January 2, 2025.

Summary

• Frank Morich, a director of Cue Biopharma, Inc., was granted a stock option to purchase 24,400 shares of common stock.
• The options have an exercise price of $1.09 per share.
• The grant date was January 2, 2025.
• The options vest in two tranches: 50% on the six-month anniversary of the grant date and the remaining 50% on the first anniversary of the grant date.
• The options expire on January 1, 2035.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to director compensation, which is neither particularly positive nor negative. It reflects standard corporate governance practices.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Stock option grants are a typical component, often vesting over several years to encourage long-term commitment.
• Comparing the size and vesting schedule of this grant to those of directors at comparable companies (e.g., other small-cap biotech firms) would provide a benchmark for assessing its competitiveness.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to act in the best interests of the company, which could benefit all stakeholders.

Key Dates